Plasma Amyloid‐β 40 as a Potential Biomarker in Cerebral Amyloid Angiopathy

Abstract

AbstractBackgroundWe aimed to analyze plasma amyloid‐β (Aβ) using a highly sensitive nano‐biosensing platform to demonstrate the possibility of precise cerebral amyloid angiopathy (CAA) diagnosis in participants classified according to amyloid PET positivity and the neuroimaging criteria for CAA.MethodA total of 25 normal controls (NC) and 19 patients with Alzheimer’s disease (AD), which were further classified into the CAA− and CAA+ groups according to the modified Boston criteria were recruited in this study. All participants underwent plasma Aβ analysis using a highly sensitive nano‐biosensing platform, amyloid PET scanning, and detailed neuropsychological testing.ResultThe average signal levels of plasma Aβ42/40 differed significantly between the NC and AD groups, and the CAA+ group exhibited significantly higher plasma Aβ40 signal levels than the CAA− group in both NC and AD groups. The concordance between the plasma Aβ40 signal level and the neuroimaging criteria for CAA was nearly perfect. Higher plasma Aβ40 signal levels were significantly associated with the presence of CAA based on the regression analyses, and the neuroimaging pattern analysis partly supported this result.ConclusionOur findings suggest that measuring plasma Aβ40 using a highly sensitive nano‐biosensing platform could be a useful non‐invasive diagnostic method for detecting CAA.